ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1–Infected, Antiretroviral Therapy–Naive Subjects

Background. Dolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF). Methods. ING116070 is an ongoing, single-arm, open-label, multicenter study in antiretroviral therapy–nai...

Descripción completa

Detalles Bibliográficos
Autores principales: Letendre, Scott L., Mills, Anthony M., Tashima, Karen T., Thomas, Deborah A., Min, Sherene S., Chen, Shuguang, Song, Ivy H., Piscitelli, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
HIV/AIDS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166983/
https://www.ncbi.nlm.nih.gov/pubmed/24944232
http://dx.doi.org/10.1093/cid/ciu477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166983/
https://www.ncbi.nlm.nih.gov/pubmed/24944232
http://dx.doi.org/10.1093/cid/ciu477

Ejemplares similares